The global cancer diagnostics market to reach US$ 136.3 Bn in 2029 growing at compound annual growth rate (CAGR) of 6.1% during the forecast period from 2021 to 2029. The prime factors driving the global cancer diagnostics market is the rising prevalence of cancer worldwide. As per the World Health Organization (WHO), cancer accounted for the second leading cause of mortality, claiming to 8.8 million deaths in 2015 globally. The National Cancer Institute estimated around 1,685,210 new cancer cases in 2019 in the United States. As per the Centers for Disease Control and Prevention (CDC), cancer cases anticipated to increase by 2 million each year by 2020.
The medical marijuana market is set to reach US$ 57,582.5 Mn by 2026 from US$ 13,908.7 Mn in 2017 at a compound annual growth rate (CAGR) of 17.1% during the forecast period from 2018 to 2026. According to the International Association for the Study of Pain (IASP) any pain persisting for more than six months in defined as chronic pain.
The global cervical cancer diagnostic test market is growing significantly, was valued at US$ 8,779.2 Mn in 2017 and expected to attain US$ XX Mn by 2026. Worldwide growing prevalence of cervical cancer along with growing female population aged between 25 to 60 years are the major factors driving the overall growth of the global cervical cancer diagnostic test market.
The global nanoemulsion market projected to reach US$ 14,760.4 Mn by 2026 from US$ 6,827.5 Mn in 2017, growing at a CAGR of 8.9% during the forecast period from 2018 to 2026. Technically nanoemulsions are thermodynamically stable, isotropic, translucent or transparent, and dispersions of oil & water stabilized with a film linking surfactant molecules with a droplet size of 20 to 500nm.
The global blood flow measurement devices market accounted for a value of US$ Mn in 2017 and expected to attain US$ Mn by 2026. Drivers responsible for the market growth are globally growing elderly population coupled with rising prevalence of chronic diseases, increasing preference from users for noninvasive devices, and mounting technological developments in blood flow meters.
The global endobronchial ultrasound biopsy devices market accounted for a value of US$ 492.0 Mn in 2017 and expected to attain US$ 753.6 Mn by 2026. Worldwide growing elderly population coupled with increasing prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD), lung cancer, pleural mesothelioma, and tuberculosis (TB) anticipated to foster the market growth over the forecast period.
The global blood-brain barrier market projected to reach US$ 5,704.2 Mn by 2026 from US$ 696.4 Mn in 2017, growing at a CAGR of 25.0% during the forecast period from 2018 to 2026. The blood-brain barrier (BBB) prevents free flow of elements from circulatory system to the cerebrospinal fluid (CSF) or brain with specific exchange of elements regulated by blood-brain barrier and blood-CSF barrier.
The oncology biosimilars market stood at US$ 3520.9 Mn in 2021 and projected to exhibit a double-digit compound annual growth rate (CAGR) of 28.3% during the forecast period from 2025 to 2033. According to U.S. Food and Drug Administration, biosimilars are biological medicines that contain a highly similar version of the active substance of an already approved biologic, commonly referred to as the reference product.
Single photon emission computed tomography (SPECT) is a form of non-invasive nuclear medicine tomographic imaging technique that utilizes gamma rays to provide 3D information of body organs (inside view). This system uses a radioactive substance and a special camera to create 3-D pictures which display the blood flow to tissues & organs thereby assisting doctors to diagnose or monitor brain disorders, bone disorders, and heart problems.
The global medical imaging software market is projected to grow at a CAGR of 7.2% during the forecast period of 2025 to 2033, driven by factors such as the increasing prevalence of chronic diseases, advancements in imaging technology, and the rising demand for efficient and accurate diagnostic solutions. This market encompasses software solutions that are crucial in acquiring, processing, visualizing, and analyzing medical images. These solutions enable healthcare professionals to effectively diagnose and treat various medical conditions by creating visual representations of the internal structures of the body.
The oncology drugs market is a critical segment of the pharmaceutical industry, providing innovative solutions for the treatment of cancer. The market is driven by the increasing prevalence of cancer worldwide, advancements in technology, and the emergence of personalized medicine. The oncology drugs market is a highly competitive and dynamic market, with many companies focusing on the development of novel therapies to treat cancer. One of the primary drivers of the oncology drugs market is the increasing prevalence of cancer worldwide. According to the World Health Organization (WHO), cancer is one of the leading causes of death globally, accounting for approximately 9.6 million deaths in 2018. The rising incidence of cancer has led to an increased demand for innovative oncology drugs, driving the growth of the market.
The global oncology drugs market is expected to grow at a CAGR of 13% during the period of 2023 to 2031. The increasing demand for new therapies, coupled with advancements in technology and an increasing focus on personalized medicine, is expected to drive the growth of the market in the coming years. One of the emerging trends in the oncology drugs market is the increasing use of immunotherapy. Immunotherapy involves the use of drugs that stimulate the body's immune system to attack cancer cells. Immunotherapy has shown promising results in the treatment of several types of cancer, including melanoma, lung cancer, and bladder cancer. The development of immunotherapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the oncology drugs market. Another trend in the oncology drugs market is the increasing focus on precision medicine. Precision medicine involves tailoring medical treatments to individual patients based on their unique genetic and molecular profiles. The development of precision medicine requires the use of advanced diagnostic tools and drug discovery technologies, which have contributed to the growth of the oncology drugs market.
The increasing focus on targeted therapies is also driving the growth of the oncology drugs market. Targeted therapies are drugs that are designed to target specific molecules that are involved in the growth and spread of cancer cells. Targeted therapies can be more effective than traditional chemotherapy, as they have fewer side effects and are more specific in their action. The development of targeted therapies requires the use of advanced drug discovery technologies, which has contributed to the growth of the oncology drugs market.
The increasing use of combination therapies is driving the growth of the oncology drugs market. Combination therapies involve the use of two or more drugs to treat cancer. Combination therapies can improve patient outcomes by targeting multiple pathways involved in the disease process. The development of combination therapies requires the use of advanced drug discovery technologies and clinical trial design, which has contributed to the growth of the oncology drugs market. The oncology drugs market is a critical segment of the pharmaceutical industry, providing innovative solutions for the treatment of cancer. The increasing prevalence of cancer worldwide, advancements in technology, and emerging trends in immunotherapy, precision medicine, targeted therapies, and combination therapies are expected to drive the growth of the oncology drugs market. As the demand for new and effective therapies continues to increase, the oncology drugs market is expected to remain a critical component of the pharmaceutical industry in the coming years. Companies that provide oncology drugs and related services are well-positioned to capitalize on this growing market.
